01.01.06
Indication: Migraine
Source: Cephalalgia, November 2005; 25(11):1031-41.
Research: Researchers carried out a study in 170 migraine patients. At the start of the study, subjects were experiencing five attacks on average over a four-week period. The subjects were randomly assigned to receive MIG-99 three times a day or placebo for up to four months. The primary endpoint was the average number of migraine attacks per 28 days during the treatment months two and three compared with baseline.
Results: In the feverfew group, migraine frequency declined by two attacks per month. In the placebo patients, the corresponding decrease was only one per month. Researchers concluded that the feverfew preparation was 3.4 times more effective than placebo. They also deemed the benefit-risk ratio to be favorable.
Source: Cephalalgia, November 2005; 25(11):1031-41.
Research: Researchers carried out a study in 170 migraine patients. At the start of the study, subjects were experiencing five attacks on average over a four-week period. The subjects were randomly assigned to receive MIG-99 three times a day or placebo for up to four months. The primary endpoint was the average number of migraine attacks per 28 days during the treatment months two and three compared with baseline.
Results: In the feverfew group, migraine frequency declined by two attacks per month. In the placebo patients, the corresponding decrease was only one per month. Researchers concluded that the feverfew preparation was 3.4 times more effective than placebo. They also deemed the benefit-risk ratio to be favorable.